ClinicalTrials.gg
TerminatedNCT06219239Updated Nov 4, 2026

Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients

An interventional study of KL003 cell injection Drug Product in Transfusion-dependent Beta-Thalassemia, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Terminated at 1 site in China. Open to participants aged 3 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Suboptimal treatment response
Updated Nov 4, 2026Now TerminatedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
3 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in beta-Thalassemia with a site in China — 20 open to participants now, 25 under way, 1 of them phase 3. beta-Thalassemia · China.

Enrollment
27th of 34
3 · median 10
Started
2024
with 10 others
No phase
13 of 44
4 open now
Registered
30th of 44
by date
Lead sponsor
6 of 44
Institute of Hematology & Blood Diseases Hospital, China

Among the 44 studies in beta-Thalassemia with a site in China, this one is the 27th largest by enrollment of the 34 interventional ones that give a count, is one of 11 that started in 2024, is one of 13 with no phase, and was the 30th registered.

beta-Thalassemia

295 studies on the registry are indexed under beta-Thalassemia; 70 are open to participants now.

Browse beta-Thalassemia studies →

Open to participants now

20 of the 44 studies in beta-Thalassemia with a site in China are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.

This study: 3 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in beta-Thalassemia with a site in China, or all of them as a file.
02

Study summary

This is a non-randomized, open-label, single-dose study. The aim of this study is to evaluate the safety and efficacy of the treatment with lentiviral vector encoding βA-T87Q-globin gene transduced autologous hematopoietic stem cells transfusion in subjects with transfusion-dependent β-thalassemia.

03

Conditions studied

  • Transfusion-dependent Beta-Thalassemia

Browse trials for

Keywords

  • Beta-Thalassemia
  • Hematopoietic Stem-Cell Transplantation
  • KL003
  • Gene therapy
  • no conditioning regimen
04

Who can participate

Ages eligible
3 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female age between 3-35 years
  • Diagnosis of transfusion-dependent β-thalassemia and a history of at least 100 mL/kg/year of pRBCs or ≥8 transfusions of pRBCs per year for the prior 2 years
  • Documented baseline, or pretransfusion, level≤7 g/dL
  • performance status ≥70 for subjects≥16 years of age; Lansky performance status of ≥70 for subjects\<16 years of age
  • Eligible to undergo
  • Willing and able to follow the research procedures and conditions, with good compliance
  • Willing to receive at least the 2 years follow-up and maintain detailed medical records, including transfusion history
  • Subject and/or legal guardians voluntarily participated in this clinical trial and signed the form, and can complete all follow-ups in accordance with the protocol requirements

Exclusion criteria

Exclusion Criteria:

  • Presence of clear for hematopoietic stem cell collection
  • Diagnosis of composite α thalassemia
  • A white blood cell (WBC) count \<3×10\^9/L, and/or count \<100×10\^9/L not related to hypersplenism
  • Subjects with severe iron overload at the time of screening: severe iron overload of the liver showed by MRI, serum ferritin ≥ 5000 ng/mL, or moderate to severe iron overload of the heart
  • Any prior or current or myeloproliferative or significant immunodeficiency disorder
  • Meet the criteria for and with an identified willing donor with a full HLA match
  • Prior receipt of gene therapy or allo-HSCT
  • Subjects with any severe active fungal, bacterial, viral, tuberculosis or other infection, including active (defined as serum HBV-DNA ≥2000 IU/ml), active virus, HCV) infection, (HIV) antibody-positive or active syphilis patients, etc.
  • Immediate family member (i.e. parent or siblings) with a known Familial Cancer Syndrome (including but not limited to hereditary breast and ovarian cancer syndrome, hereditary non-polyposis colorectal cancer syndrome and familial adenomatous polyposis)
  • Diagnosis of a significant psychiatric disorder of the subject that could seriously impede the ability to participate in the study
  • History of major organ damage including:

    1. Liver function test suggest or ALT levels >3× (ULN);
    2. Total serum value >2.5×ULN;if combined with Gilbert syndrome, total bilirubin >3×ULN and direct bilirubin value >2.5×ULN;
    3. History of bridging fibrosis, cirrhosis;
    4. \<45%;
    5. (NYHA) class III or IV congestive heart failure;
    6. Severe arrhythmia requiring medical treatment;
    7. Uncontrolled hypertension or unstable angina pectoris;
    8. Myocardial infarction or bypass or stent surgery within 12 months before drug administration;
    9. Valvular disease with clinical significance;
    10. Baseline calculated \<60mL/min/1.73m2;
    11. Pulmonary function: /FVC\<60% and/or diffusion capacity of carbon monoxide (DLco) \<60% of prediction;
    12. Evidence of pulmonary hypertension requiring medical intervention.
  • Uncorrectable coagulation dysfunction or history of severe bleeding disorder
  • Any other condition that would render the subject ineligible for HSCT, as determined by the attending transplant physician
  • Known allergy to clinical trial drug (plerixafor or G-CSF or busulfan) or ingredient(DMSO etc.)
  • Participated in other clinical studies within 3 months prior to screening
  • Inoculated within 6 weeks prior to screening
  • Pregnancy or breastfeeding women; Subjects or their sexual partners were unable to take medically recognized effective measures during the 27-month study period
  • The subjects or their parents would not comply with the study procedures outlined in the protocol
  • The subjects received hydroxyurea or thalidomide or hypomethylating drugs within 3 months before hematopoietic stem cell collection
  • Patients considered to be ineligible for the study by the investigator for reasons other than the above
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    KL003 cell injection Drug Product

    Traditional myeloablative conditioning regimen consists of Busulfan, which may increase the risk of irreversible pulmonary fibrosis, VOD, and infertility due to potential serious toxicity. In this study, we intend to use genetic hematopoietic stem cells (lentivirus transduction) transfusion with no conditioning regimen, which could avoid toxicity due to chemotherapy drugs.

    Genetic: KL003 cell injection Drug Product

Interventions

  • GeneticKL003 cell injection Drug Product

    No conditioning regimen for transfusion of auto-HSC transduced with lentiviral vector encoding βA-T87Q-globin gene

06

What researchers measure

Primary outcomes

  1. The number, frequency and severity of adverse events (AE) after reinfusion of KL003 drug products

    Time frame: within 6 months

  2. The proportion of participants who meet the definition of transfusion independence (TI) for at least 6 months

    TI is defined as Hb ≥ 90.0 g/L after reinfusion and without disease-related routine blood transfusion for 6 months

    Time frame: Up to 24 months post transplant

07

Study locations

1 site
  • Institute of Hematology & Blood Diseases Hospital
    Tianjin, Tianjin Municipality 300020, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jan 2024 to primary completion in Dec 2025, 23 months.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Dec 2025, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2024
First posted
Jan 23, 2024
StartActual
Jan 4, 2024
Primary completionActual
Dec 31, 2025
CompletionActual
Dec 31, 2025was Dec 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Suboptimal treatment response
changed Nov 4, 2026
Study completion
Dec 31, 2026→Dec 31, 2025 (actual)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Recruiting→Terminated
    Why stopped Suboptimal treatment response
    Study completion Dec 31, 2026→Dec 31, 2025 (now actual)
    + 5 other changes: verification date, responsible party, oversight details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06219239
Collaborators
Kanglin Biotech
Responsible party
Jun Shi (Director of Red Blood Cell Diseases Center, Institute of Hematology & Blood Diseases Hospital, China) — Principal investigator
First posted
Jan 23, 2024
Start date
Jan 4, 2024
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025
Last update
Nov 4, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion